Amphastar Pharmaceuticals (AMPH) Raw Materials (2015 - 2026)

Amphastar Pharmaceuticals' Raw Materials history runs 12 years deep, the most recent figure standing at $104.7 million for Q1 2026.

• In Q1 2026, Raw Materials rose 1.37% year-over-year to $104.7 million; the TTM figure through Mar 2026 stood at $104.7 million (up 1.37% YoY), while the FY2025 annual figure was $106.8 million, up 31.06% from the prior year.
• Raw Materials was $104.7 million for Q1 2026 at Amphastar Pharmaceuticals, down from $106.8 million in the prior quarter.
• In the past five years, Raw Materials ranged from a high of $106.8 million in Q4 2025 to a low of $40.4 million in Q1 2022.
• Historically, Raw Materials has averaged $67.9 million across 5 years, with a median of $55.2 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Raw Materials retreated 6.7% in 2022, then surged 100.84% in 2025.
• A 5-year view of Raw Materials shows it stood at $47.6 million in 2022, then grew by 5.2% to $50.1 million in 2023, then jumped by 62.76% to $81.5 million in 2024, then surged by 31.06% to $106.8 million in 2025, then slipped by 2.03% to $104.7 million in 2026.
• The last three Raw Materials figures came in at $104.7 million (Q1 2026), $106.8 million (Q4 2025), and $105.8 million (Q3 2025), per Business Quant data.